RFdiffusion designs epitope-specific VHHs, scFvs and antibodies de novo
Source check: Needs source check. Not independent scientific confirmation.
Finding: Cryo-EM structures confirmed binding pose of designed VHHs against influenza haemagglutinin and C. difficile TcdB; initial designs had tens to hundreds of nanomolar Kd, improved by affinity maturation. Therapeutic benefit not shown. Cryo-EM confirms pose for two VHH designs; scFv/full-antibody and other epitopes characterized less deeply.
Technology: Fine-tuned RFdiffusion (RFdiffusion2-based) network plus yeast display
Family RFdiffusion: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Fine-tuned RFdiffusion generated antibody CDR/framework designs that were screened by yeast display.
- Test and result
- Cryo-EM structures confirmed binding pose of designed VHHs against influenza haemagglutinin and C. difficile TcdB; initial designs had tens to hundreds of nanomolar Kd, improved by affinity maturation. Therapeutic benefit not shown.
- Limitation / still unknown
- Cryo-EM confirms pose for two VHH designs; scFv/full-antibody and other epitopes characterized less deeply.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:%2210.1038/s41586-025-09721-5%22&resultType=core&format=json
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Abstract and metadata via Europe PMC; full text not read.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 5/5 · Validation 3/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.